Europe Antibodies Market

Europe Antibodies Market Size (2022 to 2027)

The size of the Antibodies Market in Europe is worth USD 35.41 Billion in 2022. It is estimated to reach USD 60.77 Billion by the end of 2027, with a growing potential of 11.41 % during the forecast period.

An efficient resource for the therapy of complex disorders with minor side effects has enhanced the growth of antibodies-based therapeutics against chemical drugs.

Innovative products primarily drive the antibody market in the European region, increasing the adoption rate of therapeutic antibodies in cost-sensitive markets, rise in chronic illnesses due to population shift and increasing longevity, quick approval for breakthrough therapies by regulatory authorities, and adoption of diagnostic antibodies.

In terms of research, the antibody market in the European region is rapidly expanding, and there is continuous innovation and advancements in the sector. The constant invention of newer, more inventive items is proven to boost market demand. In addition, extremely cost-conscious markets are now adjusting to therapeutic antibodies are expected to accelerate the growth rate of the European antibodies market. Furthermore, patients benefit from the increasing network of clinics in established and emerging economies, which increases accessibility and convenience. Furthermore, clinician knowledge of new treatments and the availability of competent people is expected to boost the market’s growth rate during the forecast period.

Along with illness prevalence, the market size will gain from increased treatment spending abilities on modern medicines. Moreover, continuing technology improvements, improved accessibility, and growing disposable income are expected to influence the industry's growth. The fertile environment for the new therapeutic antibodies, government policies are further helping the industry to flourish. The companies adapt to the changing market and orient their business plan and policies to help increase the antibodies sector.

However, the high cost of treatment and side effects associated with antibody treatment are the restraints affecting the growth of the European antibodies market.  Certain treatments, such as monoclonal antibody therapy, are costly and difficult for patients to afford. Also, the stringent regulatory system and government policies are very time-consuming and make the product's entrance more complex, resulting in fewer competitors entering the market, which limits market expansion. Furthermore, the therapy's safety and effectiveness are questioned. As a result, it is seen to be limiting the sector's growth. Fever, chills, nausea, vomiting, and other adverse effects are common with an antibody treatment. As a result, patients tend to mistrust the therapy's efficacy, limiting the sector's expansion. Also, the presence of alternative therapies and treatments in the market affects market growth.

This research report on the European antibodies market has been segmented and sub-segmented into the following categories:

By Product Type:

• Monoclonal Antibodies
  • Murine
  • Chimeric
  • Humanized
  • Human
• Polyclonal Antibodies
  • Type I
  • Type II
  • Type III
  • Type IV
  • Type V
  • Type VI
  • Type VII
  • Type VIII
• Anti-body drug complexes
  • Immunogen Technology
  • Seattle Genetics Technology
  • Immunomedics Technology

By Indication:

• Cancer
• Autoimmune Diseases
• Infectious Diseases
• Cardiovascular Diseases
• CNS Disorders
• Others (Inflammatory, Microbial Diseases, & Other)

By End User:

• Hospitals/Clinics
• Research institute
• Diagnostics laboratories

By Application:

• Medical
• Experimental
• Western blot
• ELISA
• Radioimmune Assays
• Immunofluorescence
• Others (Immunohistochemistry, Immunoprecipitation, & Immunocytochemistry)

By Country:

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

Geographically, the European region is expected to be the second-largest regional market in the global antibodies market. For the manufacture of monoclonal antibodies, European laboratories have partnered with academic institutes. As a result, Europe has a well-developed laboratory infrastructure expected to drive market demand to a high level. Furthermore, the market's growth pace is being accelerated by the rising prevalence of different health conditions. 

The researchers utilize this monoclonal antibody as a study or diagnostic tool, employing several methodological strategies for improving antibody manufacturing, such as recombinant technology. 

In 2020, Germany's revenue share in European industry was above 18 percent. Due to the growing frequency of infectious disorders such as COVID-19, the contagious disease category may expand at a 14.1 percent CAGR from 2022 to 2027, driving product research and development.

Along with illness prevalence, the market size will gain from increased treatment spending abilities on modern medicines. Moreover, the industry's development in this region will be influenced by ongoing technology improvements and improved accessibility. In addition, these industries and market players undertake growing disposable income with various strategic initiatives to extend their regional presence and product reach.

KEY MARKET PLAYERS:

A few noteworthy companies in the European antibodies market analyzed in this report are Abbott Diagnostics, Novartis AG, Pfizer Inc., Thermo Fisher Scientific Inc., Eli Lilly and company, A.G. Scientific, Inc., Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, and AbbVie Inc.